Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Dermatol. Feb 2, 2015; 4(1): 50-56
Published online Feb 2, 2015. doi: 10.5314/wjd.v4.i1.50
Primary cutaneous B cell lymphoma: Clinical features, diagnosis and treatment
Fergun Yilmaz, Nur Soyer, Filiz Vural
Fergun Yilmaz, Nur Soyer, Filiz Vural, Department of Hematology, Ege University, 35100 Izmir, Turkey
Author contributions: Yilmaz F, Soyer N and Vural F contributed to this paper.
Conflict-of-interest: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Filiz Vural, MD, Department of Hematology, Ege University Hospital, Bornova, 35100 Izmir, Turkey.
Telephone: +90-23-23904541
Received: October 2, 2014
Peer-review started: October 3, 2014
First decision: November 27, 2014
Revised: December 18, 2014
Accepted: January 9, 2015
Article in press: Janurary 12, 2015
Published online: February 2, 2015
Core Tip

Core tip: Primary cutaneous B cell lymphoma is a type of lymphoma that presents in the skin without evidence of extra-cutaneous involvement. Prognosis and treatment being different from systemic lymphomas involving the skin makes differential diagnosis very important. It is a heterogeneous group of diseases that consists of indolent (primary cutaneous marginal zone lymphoma, primary cutaneous follicle centre lymphoma) and aggressive forms (primary cutaneous diffuse large B cell lymphoma, leg type and intravascular large B cell lymphoma). The indolent forms are mostly confined to the skin and have good prognosis whereas aggressive forms present with disseminated disease and are treated mostly with systemic combination chemotherapies.